Loading patent…
AssigneeMedImmune, LLC
InventorsJennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry Watkins
Estimating the term…
The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.
An IL-9 antibody comprising a variable heavy (VH) domain having an amino acid sequence of the VH domain of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide.
An IL-9 antibody comprising a variable light (VL) domain having an amino acid sequence of the VL domain of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human 11L-9 polypeptide.
An IL-9 antibody comprising a complementarily determining region (CDR) having an amino acid sequence of a CDR of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide.
The IL-9 antibody of claim. 51, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4 H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A 10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.
A method of diagnosing, proposing, or monitoring a disorder or disease characterized by aberrant expression and/or activity of an IL-9 polypeptide or aberrant expression and/or activity of an IL-9R comprising:
An IL-9 antibody, wherein said IL-9 antibody has an association rate constant or kon, rate of at least 105 M−1 s−1.
An IL-9 antibody, wherein said IL-9 antibody has a dissociation rate constant or koff rate of less than about 2×10−4 s−1.
An IL-9 antibody, wherein said IL-9 antibody has an affinity constant (Ka) of at least 107 M−1.
An IL-9 antibody, wherein said IL-9 antibody has dissociation constant (Kd) of less than 10−9 M.
Dependencies are inferred from the claim text.